Anticipating When the FDA Will Treat Your Product as a Drug-Device Combination

January 17, 2018

Webinar

Jake M. Holdreith

Partner

Managing Partner, Minneapolis Office
Member of Executive Board

Oren D. Langer

Partner

Managing Partner, New York Office

The FDA considers a product a drug-device if it includes at least two of the following: a drug component, device component, or a biologic component. The FDA does not classify as a combination product, one that consists of similar components, e.g., drug-drug or device-device. However, bringing a combination device to market requires careful consideration of your strategy. During this session we will discuss the legal consequences of bringing your combination product to market from both a regulatory and patent litigation perspective.

Related Events

August 6, 2024
Identifying Opportunities: Affirmative Recovery Strategies
Brendan Johnson, Jamie Kurtz, Emily Tremblay - ACC MN CLE
Minneapolis, MN
October 21, 2024
How Much Did We Invest in AI?
David Prange, Emily Tremblay - LES Annual Meeting
New Orleans, LA
October 22, 2024
Trends in Trade Secret Litigation
Patrick Arenz - LES Annual Meeting
New Orleans, LA